
ALT This is an infographic titled "1-Year Outcomes of Transseptal Transcatheter Mitral Valve Replacement for Mitral Annular Calcification-Related Mitral Valve Dysfunction." It includes charts and statistics, showing expected benefits at 1 year with freedom from heart failure and survival rates. It also outlines potential risks like hemolysis and left ventricular outflow tract obstruction. A flowchart describes a process from symptomatic mitral valve dysfunction to multidisciplinary imaging and automatic screening. The source is a study by Guerrero ME, et al., in JACC 2026.

ALT Bar chart titled "Limits to AI Substitution across Specialties: Composition of Medicare Part B Payments Including E&M Services." The chart shows percentages of "Physical," "E&M," and "Nonphysical" services across 15 medical specialties and all overall (US$44.9bn). Total 2023 Medicare Part B payments are shown in parentheses (US$ bn); amounts are in billions of U.S. dollars.

ALT Two panels showing the primary efficacy and safety end points. Panel A is a bar graph that shows the median number of days alive without antibiotic therapy for infective endocarditis or bacteremia within 6 months after randomization (the primary efficacy end point) among patients in the tailored-therapy and standard-therapy groups. Panel B shows the Kaplan–Meier estimates of the probability of a composite of death from any cause, unplanned cardiac surgery, or symptomatic embolic events within 6 months after randomization (the primary safety end point).





























